Stocktoria
Upstream Bio, Inc. UPB
Upstream Bio, Inc. (UPB) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.9M at a -5026.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| UPB | Upstream Bio, Inc. | 2/9 | — | — | — |
| RNAC | Cartesian Therapeutics, Inc. | 1/9 | -10.08 | — | -92.8% |
| ONTX | Traws Pharma, Inc. | 3/9 | — | 1.4 | — |
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
| GOVX | GeoVax Labs, Inc. | 1/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
FAQ
Is UPB financially healthy?
Upstream Bio, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does UPB pay a dividend?
No, Upstream Bio, Inc. does not currently pay a dividend.
How profitable is UPB?
In FY2025, Upstream Bio, Inc. had a net margin of -5026.0% and a return on equity of -42.2%.
What is the analyst price target for UPB?
The average Wall-Street price target for Upstream Bio, Inc. is $38.25, about 453.5% above the recent price, from 8 analysts (consensus: buy).
Is UPB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Upstream Bio, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.